Advanced search

News (179)

Biophytis: Phase 3 protocol unveiled in sarcopenia	03-22	CF
Biophytis S A : presented the potential of RuvembriTM in the treatment of Duchenne Muscular Dystrophy - Form 6-K	03-08	PU
Biophytis S A : and the University of Liège explore the potential of Sarconeos (BIO101) in the treatment of viral respiratory failure - Form 6-K	12-05	PU
Biophytis S A : appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Board - Form 6-K	11-28	PU
BIOPHYTIS AND INNOVATION SOLUTIONS PHARMA SIGN A PARTNERSHIP AGREEMENT TO ACCELERATE MARKET ACCESS FOR SARCONEOS IN BRAZIL	30/10/23	AQ
Biophytis S A : announces the launch of a rights issue with maintenance of shareholders’ preferential subscription rights to continue the execution of its strategic roadmap - Form 6-K	23/10/23	PU
Biophytis S A : Interim Financial Report issued by the registrant on September 27, 2023 - Form 6-K	27/09/23	PU
BIOPHYTIS AND SKYEPHARMA SIGN A PARTNERSHIP AGREEMENT FOR THE PRODUCTION OF SARCONEOS	26/09/23	AQ
Biophytis S.A. Announces Executive Changes	14/09/23	CI
Biophytis S A : receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe - Form 6-K	25/08/23	PU
Biophytis S A : Press Release	20/07/23	PU
BIOPHYTIS AND SEQENS SIGN A PARTNERSHIP TO PRODUCE SARCONEOS	19/07/23	AQ
Biophytis applies for authorization for Sara-31 study	15/05/23	CF
Biophytis S A : Press Release dated April 18, 2023 - Form 6-K	18/04/23	PU
Biophytis S A : Results of the Combined General Meeting on April 17, 2023	17/04/23	PU
Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program	17/03/23	EQ
Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference	09/03/23	EQ
Biophytis S A : Press Release dated February 28, 2023 - Form 6-K	02/03/23	PU
Biophytis announces the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (BIO101) in France for the treatment of severe forms of COVID-1	01/03/23	EQ
Biophytis initiates the regulatory process for an early access authorization in France from the French National Authority for Health (HAS) for the treatment with Sarconeos (BIO101) of severe forms of	27/02/23	EQ
: Biophytis To Host A Combined General Shareholder’s Meeting On March 30, 2023	23/02/23	EQ
Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19	02/02/23	EQ
Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19	03/11/22	EQ
Biophytis S A : Press Release dated October 31, 2022 - Form 6-K	02/11/22	PU
Biophytis publishes its key financial figures as at 30 June 2022, announces a restatement of the financial statements published as of December 31st, 2021 and provides an update on the oper	31/10/22	EQ
Biophytis participates in H.C. Wainwright 24th Annual Global Investment Conference	15/09/22	EQ
Biophytis announces very promising top line results of its phase 2-3 COVA clinical study in COVID-19-related respiratory failure	07/09/22	EQ
Biophytis S A : to update on the development of Sarconeos (BIO101) in Covid-19 at the 4th Annual Longevity Therapeutics Summit - Form 6-K	05/07/22	PU
Biophytis SA to Update on the Development of Sarconeos in Covid-19 at 4th Annual Longevity Therapeutics Summit	05/07/22	CI
Biophytis S A : presents the development of Sarconeos (BIO101) in Phase 3 for the treatment of Sarcopenia at the 15th SCWD International Congress - Form 6-K	28/06/22	PU
Biophytis presents the development of Sarconeos (BIO101) in Phase 3 for the treatment of Sarcopenia at the 15th SCWD International Congress	27/06/22	EQ
Biophytis: Results of the Combined General Meeting on June 21, 2022 All ordinary and extraordinary resolutions presented by the company have been adopted	22/06/22	EQ
Biophytis S A : presents preclinical efficacy data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a rare neuromuscular disease - Form 6-K	16/06/22	PU
Biophytis presents preclinical efficacy data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a rare neuromuscular disease	16/06/22	EQ
Biophytis: Biophytis announces its participation at the BIO International Convention in San Diego from the 13th to the 16th of June	12/05/22	EQ
Biophytis S A : €23.9M of available cash on December 31 2021 and new financing instruments for a total of €42M allowing financial visibility beyond mid 2023 - Form 6-K	07/04/22	PU
Biophytis provides updates on Sarconeos (BIO101) clinical development	07/04/22	EQ
Biophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives	07/04/22	EQ
Biophytis S A : appoints Philippe Rousseau as Chief Financial Officer - Form 6-K	06/04/22	PU
Biophytis appoints Philippe Rousseau as Chief Financial Officer	05/04/22	EQ
Biophytis S A : received approval from ANVISA (Brazil) to give access to Sarconeos (BIO101) to hospitalized COVID-19 patients through an Expanded Access Program - Form 6-K	03/02/22	PU
Biophytis received approval from ANVISA (Brazil) to give access to Sarconeos (BIO101) to hospitalized COVID-19 patients through an Expanded Access Program	03/02/22	EQ
Biophytis S A : to meet with FDA to advance Sarconeos (BIO101) development in Sarcopenia from Phase 2 to Phase 3 - Form 6-K	17/12/21	PU
Biophytis to meet with FDA to advance Sarconeos (BIO101) development in Sarcopenia from Phase 2 to Phase 3	16/12/21	EQ
Biophytis S A : obtains a new 10M€ loan structure with Kreos Capital - Form 6-K	23/11/21	PU

1234NextSee all

Insiders

Stanislas Veillet

Stanislas Veillet is the founder.
He founded Biophytis SA in 2006 and currently holds the title of Chairman, President & Chief Executive Officer.
He is also currently the Chairman of Biophytis, Inc. and an Independent Director at Drone Volt SA. In the past, he worked as a Research Director at Danone SA, Pharmacia SAS, and Cargill France SAS.
He obtained a doctorate degree from AgroParisTech.

Eloïse Catherine Brigitte Veillet

Eloïse Catherine Brigitte Veillet worked as an Analyst at Société Générale SA (UK) from 2008 to 2012.
She then worked as a Senior Analyst at Marble Bar Asset Management LLP from 2012 to 2014.
She also worked as an Analyst at SG Securities (Paris) SAS and as a Senior Consumer Analyst at DSAM Partners LLP.

No results for this search

Stock Market
Advanced search
Stanislas Veillet